Centers | ||
|
|
|
EU-OPENSCREEN | Edinburgh Drug Discovery | test |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
sfgd |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Merck Serono and Feinstein Institute to Develop New Drugs to Treat LupusMerck Serono and Feinstein Institute the research arm of North Shore-Long Island Jewish Health System in New York have entered into a joint collaboration to develop new antibody based therapies to treat Systemic Lupus Erythematosus (SLE). Merck... View all CDRD |